Evidence map›Paper›PMID 42761007›Full record

ArticleFrontiers in oncology2026

Metabolites from blood and formalin-fixed, paraffin-embedded tissue from participants with low- and high-grade prostate cancer: a pilot study.

Rebecca E Graff, Henrik L Bengtsson, Jung H Suh, Adam B Olshen, Elizabeth Y Wang, Ryan M Allen, Erin L Van Blarigan, Stacey A Kenfield, Janet E Cowan, Peter R Carroll and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rebecca E GraffDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States.
Henrik L BengtssonDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States.
Jung H SuhDenali Therapeutics, San Francisco, CA, United States.
Adam B OlshenDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States.
Elizabeth Y WangDepartment of Surgery, John A. Burns School of Medicine, University of Hawai`i at Manoa, Honolulu, HI, United States.
Ryan M AllenLoyola University Medical Center, Chicago, IL, United States.
Erin L Van BlariganDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States.
Stacey A KenfieldDepartment of Urology, University of California, San Francisco, San Francisco, CA, United States.
Janet E CowanDepartment of Urology, University of California, San Francisco, San Francisco, CA, United States.
Peter R CarrollDepartment of Urology, University of California, San Francisco, San Francisco, CA, United States.
Jeff SimkoDepartment of Pathology, University of California, San Francisco, San Francisco, CA, United States.
June M ChanDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States.

Funding

Effect of Aerobic Exercise on Genomic Signatures of Prostate Cancer PrognosisR01CA181802 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHAN, JUNE ML · 2014 to 2019
$3.1M
NCI NIH HHS R01 CA181802
6 · The paper itself

Abstract

Background: Identifying metabolites associated with prostate cancer (Pca) aggressiveness may elucidate mechanisms underlying disease severity. Doing so in plasma and formalin-fixed, paraffin-embedded (FFPE) tissue may accelerate discovery. In this cross-sectional pilot study, we generated hypotheses for further exploration by assessing the association between plasma metabolites and the Gleason score of individuals with Pca and by evaluating the correlation between plasma and FFPE metabolite levels. Methods: We examined plasma and FFPE samples from 10 individuals with Gleason score 7 (6 3 + 4, 4 4 + 3) and 9 individuals with Gleason score 9 (6 4 + 5, 3 5 + 4) tumors from a convenience sample of 19 men with Pca. We measured the relative abundance of polar metabolites at the time of radical prostatectomy. We used linear models of log Results: Among the 18 selected plasma metabolites, which were chosen Conclusions: Plasma serine and ornithine levels demonstrated the largest differences between individuals with Gleason 7 and Gleason 9 Pca. Metabolite levels in FFPE prostate tissue samples were moderately correlated with plasma levels. Future studies with larger sample sizes are needed to further explore the hypotheses generated by this study.

Indexed as

FFPEGleason scoremetabolomicsplasmaprostate cancer

Identifiers

PMID42761007
PMCPMC13585655

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.